FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200151472> ?p ?o ?g. }

• W4200151472 endingPage "27" @default.
• W4200151472 startingPage "27" @default.
• W4200151472 abstract "Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a severe prognosis, and with a long-standing need for more effective therapeutic approaches. However, treatment with immune checkpoint inhibitors is becoming an increasingly effective strategy for MPM patients. In this scenario, epigenetic modifications may negatively regulate the interplay between immune and malignant cells within the tumor microenvironment, thus contributing to the highly immunosuppressive contexture of MPM that may limit the efficacy of immunotherapy. Aiming to further improve prospectively the clinical efficacy of immunotherapeutic approaches in MPM, we investigated the immunomodulatory potential of different classes of epigenetic drugs (i.e., DNA hypomethylating agent (DHA) guadecitabine, histone deacetylase inhibitors VPA and SAHA, or EZH2 inhibitors EPZ-6438) in epithelioid, biphasic, and sarcomatoid MPM cell lines, by cytofluorimetric and real-time PCR analyses. We also characterized the effects of the DHA, guadecitabine, on the gene expression profiles (GEP) of the investigated MPM cell lines by the nCounter platform. Among investigated drugs, exposure of MPM cells to guadecitabine, either alone or in combination with VPA, SAHA and EPZ-6438 demonstrated to be the main driver of the induction/upregulation of immune molecules functionally crucial in host-tumor interaction (i.e., HLA class I, ICAM-1 and cancer testis antigens) in all three MPM subtypes investigated. Additionally, GEP demonstrated that treatment with guadecitabine led to the activation of genes involved in several immune-related functional classes mainly in the sarcomatoid subtype. Furthermore, among investigated MPM subtypes, DHA-induced CDH1 expression that contributes to restoring the epithelial phenotype was highest in sarcomatoid cells. Altogether, our results contribute to providing the rationale to develop new epigenetically-based immunotherapeutic approaches for MPM patients, potentially tailored to the specific histologic subtypes." @default.
• W4200151472 created "2021-12-31" @default.
• W4200151472 creator A5004173750 @default.
• W4200151472 creator A5004497401 @default.
• W4200151472 creator A5005367043 @default.
• W4200151472 creator A5008516429 @default.
• W4200151472 creator A5018536695 @default.
• W4200151472 creator A5051777822 @default.
• W4200151472 creator A5055372994 @default.
• W4200151472 creator A5058660055 @default.
• W4200151472 creator A5060201003 @default.
• W4200151472 creator A5072866485 @default.
• W4200151472 creator A5079933837 @default.
• W4200151472 creator A5086298433 @default.
• W4200151472 creator A5088021561 @default.
• W4200151472 creator A9999999999 @default.
• W4200151472 date "2021-12-14" @default.
• W4200151472 modified "2023-09-23" @default.
• W4200151472 title "Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy" @default.
• W4200151472 cites W1571520647 @default.
• W4200151472 cites W1827923022 @default.
• W4200151472 cites W1917736788 @default.
• W4200151472 cites W1953890763 @default.
• W4200151472 cites W2000761432 @default.
• W4200151472 cites W2008784906 @default.
• W4200151472 cites W2011482524 @default.
• W4200151472 cites W2033612699 @default.
• W4200151472 cites W2040353607 @default.
• W4200151472 cites W2057968053 @default.
• W4200151472 cites W2058481709 @default.
• W4200151472 cites W2088945149 @default.
• W4200151472 cites W2090836265 @default.
• W4200151472 cites W2103021272 @default.
• W4200151472 cites W2103524216 @default.
• W4200151472 cites W2125894767 @default.
• W4200151472 cites W2162686855 @default.
• W4200151472 cites W2165190419 @default.
• W4200151472 cites W2522313999 @default.
• W4200151472 cites W2613709564 @default.
• W4200151472 cites W2613990808 @default.
• W4200151472 cites W2739145658 @default.
• W4200151472 cites W2769074301 @default.
• W4200151472 cites W2792913923 @default.
• W4200151472 cites W2801062708 @default.
• W4200151472 cites W2802731336 @default.
• W4200151472 cites W2807952969 @default.
• W4200151472 cites W2808497725 @default.
• W4200151472 cites W2883358250 @default.
• W4200151472 cites W2888149084 @default.
• W4200151472 cites W2892042921 @default.
• W4200151472 cites W2902610962 @default.
• W4200151472 cites W2907850855 @default.
• W4200151472 cites W2908887190 @default.
• W4200151472 cites W2909198142 @default.
• W4200151472 cites W2915473767 @default.
• W4200151472 cites W2918453079 @default.
• W4200151472 cites W2963723040 @default.
• W4200151472 cites W2973246174 @default.
• W4200151472 cites W2975888204 @default.
• W4200151472 cites W2980414523 @default.
• W4200151472 cites W2992592311 @default.
• W4200151472 cites W2994978090 @default.
• W4200151472 cites W3010685956 @default.
• W4200151472 cites W3011114012 @default.
• W4200151472 cites W3014008456 @default.
• W4200151472 cites W3018674756 @default.
• W4200151472 cites W3035239631 @default.
• W4200151472 cites W3122627530 @default.
• W4200151472 cites W3128920907 @default.
• W4200151472 cites W3153820261 @default.
• W4200151472 cites W4376522462 @default.
• W4200151472 doi "https://doi.org/10.3390/epigenomes5040027" @default.
• W4200151472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34968251" @default.
• W4200151472 hasPublicationYear "2021" @default.
• W4200151472 type Work @default.
• W4200151472 citedByCount "1" @default.
• W4200151472 countsByYear W42001514722022 @default.
• W4200151472 crossrefType "journal-article" @default.
• W4200151472 hasAuthorship W4200151472A5004173750 @default.
• W4200151472 hasAuthorship W4200151472A5004497401 @default.
• W4200151472 hasAuthorship W4200151472A5005367043 @default.
• W4200151472 hasAuthorship W4200151472A5008516429 @default.
• W4200151472 hasAuthorship W4200151472A5018536695 @default.
• W4200151472 hasAuthorship W4200151472A5051777822 @default.
• W4200151472 hasAuthorship W4200151472A5055372994 @default.
• W4200151472 hasAuthorship W4200151472A5058660055 @default.
• W4200151472 hasAuthorship W4200151472A5060201003 @default.
• W4200151472 hasAuthorship W4200151472A5072866485 @default.
• W4200151472 hasAuthorship W4200151472A5079933837 @default.
• W4200151472 hasAuthorship W4200151472A5086298433 @default.
• W4200151472 hasAuthorship W4200151472A5088021561 @default.
• W4200151472 hasAuthorship W4200151472A9999999999 @default.
• W4200151472 hasBestOaLocation W42001514721 @default.
• W4200151472 hasConcept C104317684 @default.
• W4200151472 hasConcept C142724271 @default.
• W4200151472 hasConcept C150194340 @default.
• W4200151472 hasConcept C190727270 @default.
• W4200151472 hasConcept C203014093 @default.

• next